Van den Bosch
In its 2022 annual report, New Brunswick health care giant Johnson & Johnson announced its medical devices division would rebrand as Johnson & Johnson MedTech.
On May 9, the company said it appointed Kurt Van den Bosch as chief financial officer, group finance, for the division.
Van den Bosch, who will report directly to J&J Executive Vice President and Chief Financial Officer Joe Wolk, will be responsible for providing financial leadership to the global MedTech organization, driving growth with innovative medical technology.
He will be based in Belgium, acting through Johnson & Johnson’s Belgian branch, company spokesman Ryan Carbain told NJBIZ.
According to the hiring announcement, Van den Bosch most recently served as area vice president, Mid-sized Markets for J&J MedTech EMEA, where he oversaw and developed growth strategies for the markets of Austria, Belgium, Greece, Israel, Portugal, Switzerland, the Netherlands and Scandinavian countries.
Van den Bosch joined Janssen Pharmaceuticals, Belgium, in 1990 as part of the finance team. He served as CFO for Janssen EMEA from 2012 to 2014 and was then named chief financial officer for Global Surgery EMEA; in 2015 he was named to same position for Medical Devices EMEA.
He earned a master’s degree in applied economic sciences from the University of Leuven in Belgium.
In November 2021, J&J announced its plans to split into two publicly traded companies: one focusing on consumer health products and the other on pharmaceutical and medical device operations.
In the March 7 rebranding announcement for the medical device operations, Ashley McEvoy, executive vice president, worldwide chairman of the MedTech division, explained the change, “Our business sits at the compelling intersection of medical devices and medical technology, and as the world’s most broadly based medtech company, we are committed to delivering breakthrough scientific innovation and reimagining health in an increasingly digital world.
“As we continue to innovate for the future, it’s important that our new sector identity reflects our global leadership as a medtech innovator positively impacting the health of millions of patients around the world,” she said.
